HUP9901562A3 - Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system - Google Patents

Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Info

Publication number
HUP9901562A3
HUP9901562A3 HU9901562A HUP9901562A HUP9901562A3 HU P9901562 A3 HUP9901562 A3 HU P9901562A3 HU 9901562 A HU9901562 A HU 9901562A HU P9901562 A HUP9901562 A HU P9901562A HU P9901562 A3 HUP9901562 A3 HU P9901562A3
Authority
HU
Hungary
Prior art keywords
antibody
cea
conjugates
therapeutic use
monoclonal antibody
Prior art date
Application number
HU9901562A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP9901562A2 publication Critical patent/HUP9901562A2/hu
Publication of HUP9901562A3 publication Critical patent/HUP9901562A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
HU9901562A 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system HUP9901562A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein

Publications (2)

Publication Number Publication Date
HUP9901562A2 HUP9901562A2 (hu) 1999-08-30
HUP9901562A3 true HUP9901562A3 (en) 2000-06-28

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901562A HUP9901562A3 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Country Status (19)

Country Link
US (2) US6277599B1 (https=)
EP (1) EP0896626B1 (https=)
JP (1) JP2000510692A (https=)
CN (1) CN1217750A (https=)
AT (1) ATE350478T1 (https=)
AU (1) AU719513B2 (https=)
BR (1) BR9708910A (https=)
CA (1) CA2250579A1 (https=)
CZ (1) CZ353698A3 (https=)
DE (1) DE69737188T2 (https=)
ES (1) ES2279539T3 (https=)
HU (1) HUP9901562A3 (https=)
IL (1) IL126772A0 (https=)
NO (1) NO985120L (https=)
NZ (1) NZ331978A (https=)
PL (1) PL329871A1 (https=)
SK (1) SK150298A3 (https=)
TR (1) TR199802227T2 (https=)
WO (1) WO1997042329A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
AU752494B2 (en) * 1998-02-25 2002-09-19 Dow Chemical Company, The High affinity humanized ANTI-CEA monoclonal antibodies
EP1131428A2 (en) * 1998-11-19 2001-09-12 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
AU2186900A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Recombinant synthesis of beta-lipotropin and other peptides
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
ES2292587T3 (es) * 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
EP1606387A4 (en) * 2003-03-04 2008-04-23 Alexion Pharma Inc VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS
KR100872210B1 (ko) * 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
JP4982183B2 (ja) * 2003-12-12 2012-07-25 ジェネンコー・インターナショナル・インク Ｃａｂ分子
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
JP4699450B2 (ja) * 2004-04-15 2011-06-08 ジェネンコー・インターナショナル・インク Ｃａｂ分子、ｃｅａを対象とするａｄｅｐｔ構築
AU2005302459A1 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
MX339083B (es) * 2010-01-28 2016-04-01 Glaxo Group Ltd Proteinas de enlace a cd127.
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
JP7748935B2 (ja) * 2019-08-27 2025-10-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＩＬ１３Ｒα２陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成ＣＡＲ
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN115850483B (zh) * 2020-10-21 2025-09-19 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
HUP9901562A2 (hu) 1999-08-30
EP0896626B1 (en) 2007-01-03
ES2279539T3 (es) 2007-08-16
ATE350478T1 (de) 2007-01-15
PL329871A1 (en) 1999-04-12
AU2645597A (en) 1997-11-26
DE69737188T2 (de) 2007-10-11
DE69737188D1 (de) 2007-02-15
NZ331978A (en) 2000-05-26
BR9708910A (pt) 1999-08-03
CA2250579A1 (en) 1997-11-13
WO1997042329A1 (en) 1997-11-13
JP2000510692A (ja) 2000-08-22
US20020142359A1 (en) 2002-10-03
TR199802227T2 (xx) 2000-07-21
US6903203B2 (en) 2005-06-07
SK150298A3 (en) 1999-04-13
CZ353698A3 (cs) 1999-02-17
AU719513B2 (en) 2000-05-11
IL126772A0 (en) 1999-08-17
US6277599B1 (en) 2001-08-21
EP0896626A1 (en) 1999-02-17
NO985120D0 (no) 1998-11-03
NO985120L (no) 1998-12-29
CN1217750A (zh) 1999-05-26

Similar Documents

Publication Publication Date Title
HUP9901562A3 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
AU4518196A (en) Adjuvant-incorporated cellular antigens: conjugation and methods
IL129164A0 (en) Antibody against human parathormone related peptides
ZA9710409B (en) Stable lyophilised pharmaceutical preparations comprising mono- or polyclonal antibodies
IL136335A0 (en) Monoclonal human natural antibodies
AU4648697A (en) Methods and devices for preparing protein concentrates
IL120079A (en) Ultrasound system and cosmetic methods utilizing same
IL122760A0 (en) Device in inhalers
EP0672961A3 (en) Loading element and device.
PL330842A1 (en) Purified superficial sperm antigen, monoclonal antibody therefor and applications associated therewith
EP0805161A4 (en) PROTEIN BINDING (1-3) -BETA-D-GLUCANE, PROTEIN RECOGNIZING ANTIBODIES AND USE OF PROTEIN AND ANTIBODY
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
AU6128896A (en) Isoindole derivatives, their preparation and their application in therapy
GB9714971D0 (en) Assays,therapeutic methods and means
ATE186559T1 (de) Leukoindigo-präparationen in granulatform
GB2329491B (en) Collection and delivery system
IL133536A0 (en) 6-pyrrolidin-2-ylpyridine derivatives, their preparation and application in therapy
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
AU3845395A (en) Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof
AU1135595A (en) Saccharomyces-specific antigens and antibodies, their preparation and use
AU4499196A (en) Antibodies for use in cancer therapy and diagnosis
AU5279996A (en) Antibodies and their use in cancer therapy and diagnosis
GB9419256D0 (en) Antibody and conjugates
FR2735470B1 (fr) Nitrocetones et nitroximes, leur preparation et leur application en therapeutique